

---

## Two of AcouSort's board members and CEO acquire shares

**AcouSort AB (publ) ("AcouSort" or the "Company") today announces that founders and board members Thomas Laurell and Stefan Scheduling as well as CEO Torsten Freltoft have acquired shares in the Company at a value of approximately SEK 150,000. The transactions took place on 1 and 2 December 2022.**

*"My acquisition of shares in AcouSort should be seen in the light of the positive development that the Company is in. We are currently working intensively to commercialize our current product portfolio and we recently completed the highly successful BioWings project. We are now bringing BioWings' technological advances into our next major development project **AcouSome**, where the ambition is to develop a groundbreaking technology for exosome-based diagnostics. Both projects have received significant research funding from the EU. I would also like to mention that the price for the shares that I and board members Thomas Laurell and Stefan Scheduling have acquired corresponds to the exercise price for our warrants in the current option program,"* says CEO Torsten Freltoft in a comment.

For detailed information, please refer to [the Swedish Financial Supervisory Authority's website](#) for insider trading.

**For further information on AcouSort, please contact:**

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: [torsten.freltoft@acousort.com](mailto:torsten.freltoft@acousort.com)

---

### About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Erik Penser Bank, 08-463 83 00, mail to: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se) Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.